EUCTR2007-000488-38-NL进行中（未招募）不适用
Bevacizumab in combination with metronomic dose temozolomide in patients with relapsed high grade gliomas - BEvacizumab + TEmozolomide in Relapsed glioma
Academic Medical Center0 个研究点开始时间: 2007年2月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients are eligible to be included in the study if they meet all of the following criteria:
- •1. Patients present with histologically confirmed diagnosis of intracranial recurrent high grade glial tumor (WHO grade IV). Patients may be entered based on local pathology from the original tumor specimen.
- •2. Patients must have evidence of tumor progression following radiation and chemotherapy as measured by MRI (MRI-0 at presentation).
- •3. Patients may have received up to two prior chemotherapy regimens (with concurrent radiotherapy).
- •4. Patients may have undergone prior surgical resection and will be eligible if recovered from the effects of surgery.
- •5. Patients must have adequate organ function, including the following:
- •a. Adequate bone marrow reserve: Absolute neutrophil count (ANC) > 1.5 x 109/L, platelet count > 100 x 109/L, and hemoglobin > g/dL (6.21 mmol/L).
- •b. Hepatic: total bilirubin < 2 times the upper limit of normal (ULN); alkaline phosphatase (ALP), aspartate transaminase (AST), and alanine transaminase (ALT) < 3 x ULN.
- •c. Renal: Serum creatinine < 1.5 ULN.
- •These tests must be performed < 5 days prior to enrollment. Eligibility for hemoglobin count may be reached by transfusion.
- •6. Patients must have a Karnofsky Performance Score > 70%.
- •7. Patients must be > 18 years of age, with a life expectancy of greater than 8 weeks.
- •8. Patient compliance and geographic proximity that allow for adequate follow up is required.
- •9. Male and female patients with reproductive potential must use an approved contraceptive method, if appropriate (for example, intrauterine device [IUD], birth control pills, or barrier device) during and for 3 months after discontinuation of study treatment. Women with childbearing potential must have a negative serum pregnancy test < 3 days prior to study enrollment.
- •10. Signed informed consent from the patient or legal representative is required.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be excluded from the study if they meet any of the following criteria:
- •11. Patients with inability to comply with protocol or study procedures (for example, an inability to swallow tablets).
- •12. Patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- •13. Patients receiving EIAEDs (Enzyme-inducing antiepileptic drugs). Patients must discontinue EIAEDs > 14 days prior to study enrollment. The investigator may prescribe non-EIAEDs.
- •14. Patients receiving any other anticancer therapy, any anticoagulant therapy.
- •15. Patients with serious concomitant systemic disorders (for example, active infection or abnormal Electrocardiogram indicative of cardiac disease) that, in opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study.
- •16. Patients with prior thrombo-embolic events.
研究者
相似试验
尚未招募
2 期
Bevacizumab in combination with metronomic dose temozolomide in patients with relapsed high grade gliomasbrain tumorRecurrent high grade glial tumors10029211NL-OMON30453Academisch Medisch Centrum30
已完成
不适用
Avastin and Temozolomide attacking Relapsed GliomagliomabevacizumabtemozolomidePFS6NL-OMON26843Prof.dr. D.J. Richel30
已完成
不适用
AVAstin and Temozolomide Attacking Relapsed gliomaRelapsed gliomaNeoplasmsCancerISRCTN23008679Academic Medical Centre (AMC) (The Netherlands)23
招募中
不适用
Phase II study of Bevacizumab in combination with Paclitaxel in metastatic breast cancer patients with asymptomatic brain metastases.Breast CancerJPRN-UMIN000010466Kansai medical university23
进行中（未招募）
不适用
Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. - Bevacizumab + Docetaxel-Capecitabina MammellaPatients with advanced breast cancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2006-003929-83-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA